Citation Impact
Citing Papers
Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
2005 Standout
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
2007 StandoutScience
PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors
2003 StandoutScience
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
2004 StandoutScience
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
2007 Standout
Ingested Type I Interferon: A Potential Treatment for Autoimmunity
2002
Multidrug resistance in cancer: role of ATP–dependent transporters
2002 Standout
Simultaneous Activity of MRP1 and Pgp Is Correlated With In Vitro Resistance to Daunorubicin and With In Vivo Resistance in Adult Acute Myeloid Leukemia
1999
Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study.
1999
Increased expression of the breast cancer resistance protein (BCRP) in relapsed or refractory acute myeloid leukemia (AML)
2002
AML1, the Target of Multiple Chromosomal Translocations in Human Leukemia, Is Essential for Normal Fetal Liver Hematopoiesis
1996 Standout
P‐glycoprotein, lung resistance‐related protein and multidrug resistance associated protein in de novo acute non‐lymphocytic leukaemias: biological and clinical implications
1999
Reversal of multidrug resistance by the inhibition of ATP-binding cassette pumps employing “Generally Recognized As Safe” (GRAS) nanopharmaceuticals: A review
2013
Essential role of mouse telomerase in highly proliferative organs
1998 StandoutNatureNobel
Stem cells, cancer, and cancer stem cells
2001 StandoutNature
Hypoxia Regulates CD44 and Its Variant Isoforms through HIF-1α in Triple Negative Breast Cancer
2012 StandoutNobel
Chronic myelogenous leukemia
2001
Oncogenic kinase signalling
2001 StandoutNature
Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia
2002 Standout
Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer
2003 Standout
Cytogenetics in acute leukemia
2003
A Multicenter, Randomized, Controlled Clinical Trial of Transfusion Requirements in Critical Care
1999 Standout
Effect of the Tyrosine Kinase Inhibitor STI571 in a Patient with a Metastatic Gastrointestinal Stromal Tumor
2001 Standout
Principles of nanoparticle design for overcoming biological barriers to drug delivery
2015 Standout
Diagnosis and management of refractoriness to platelet transfusion
2001
The phosphatidylinositol 3-Kinase–AKT pathway in human cancer
2002 Standout
Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies
2001
Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia
2001 Standout
Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemias
2006 Standout
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells
1996 Standout
Transfusion Medicine — Blood Transfusion
1999 Standout
Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators
1990 StandoutNature
A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias
2002
What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer
2013 StandoutNobel
Anesthesiology
1997 Standout
A novel nuclear protein, 5qNCA (LOC51780) is a candidate for the myeloid leukemia tumor suppressor gene on chromosome 5 band q31
2001
Immune Thrombocytopenic Purpura
2002 Standout
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
2005 Standout
Organization and Expression of the Pseudo-Light Chain Genes in Human B-cell Ontogeny
1992
OPTIONS FOR THERAPY IN CHRONIC MYELOID LEUKAEMIA
1995
The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans
2021 StandoutNobel
Cooperation of BCR-ABL and AML1/MDS1/EVI1 in blocking myeloid differentiation and rapid induction of an acute myelogenous leukemia
2001
Hereditary Colorectal Cancer
2003 Standout
Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome
2001 Standout
ACUTE MYELOID LEUKAEMIA IN THE ELDERLY: BIOLOGY AND TREATMENT
1993
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
2013 Standout
Clonal selection and learning in the antibody system
1996 StandoutNature
Revealing the world of RNA interference
2004 StandoutNatureNobel
Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)
2002
Imatinib Mesylate — A New Oral Targeted Therapy
2002
Structural Basis for the Autoinhibition of c-Abl Tyrosine Kinase
2003 Standout
Recent advances in the growth and isolation of primitive human haemopoietic progenitor cells
1992
Underrepresentation of Patients 65 Years of Age or Older in Cancer-Treatment Trials
1999 Standout
Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2)
2003
Specific Killing of Ph+Chronic Myeloid Leukemia Cells by a Lentiviral Vector-Delivered Anti-bcr/ablSmall Hairpin RNA
2003
β-Arrestin2 mediates the initiation and progression of myeloid leukemia
2012 StandoutNobel
Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study
2001
A Double-Blind Placebo-Controlled Trial of Granulocyte Colony-Stimulating Factor in Elderly Patients With Previously Untreated Acute Myeloid Leukemia: A Southwest Oncology Group Study (9031)
1998
Multidrug resistance-associated protein in acute myeloid leukemia: No impact on treatment outcome.
1997
Parallel Phase I Studies of Daunorubicin Given With Cytarabine and Etoposide With or Without the Multidrug Resistance Modulator PSC-833 in Previously Untreated Patients 60 Years of Age or Older With Acute Myeloid Leukemia: Results of Cancer and Leukemia Group B Study 9420
1999
AML1 and the 8;21 and 3;21 translocations in acute and chronic myeloid leukemia
1995
Antitumor Antibiotics: Bleomycin, Enediynes, and Mitomycin
2005 Standout
Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
2001
Flow cytometric assay of modulation of P-glycoprotein function in whole blood by the multidrug resistance inhibitor GG918.
1996
Expression of breast cancer resistance protein in blast cells from patients with acute leukemia
2000
Acute Myeloid Leukemia in the Elderly: Assessment of Multidrug Resistance (MDR1) and Cytogenetics Distinguishes Biologic Subgroups With Remarkably Distinct Responses to Standard Chemotherapy. A Southwest Oncology Group Study
1997
Practice Guidelines for blood component therapy: A report by the American Society of Anesthesiologists Task Force on Blood Component Therapy.
1996
Functional Role of Type I and Type II Interferons in Antiviral Defense
1994 StandoutScience
Expression of breast cancer resistance protein in blast cells from patients with acute leukemia
2000
Complement Activation during Cardiopulmonary Bypass
1981 Standout
Biologic effects of leukocytes present in transfused cellular blood products
1994
TYPE I INTERFERONS (α/β) IN IMMUNITY AND AUTOIMMUNITY
2004 StandoutNobel
After chronic myelogenous leukemia: tyrosine kinase inhibitors in other hematologic malignancies
2004
Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor
2004 StandoutScience
Treatment of Philadelphia Chromosome-Positive Early Chronic Phase Chronic Myelogenous Leukemia With Daily Doses of Interferon Alpha and Low-Dose Cytarabine
1999
Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes.
1999
An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology.
1999
Cancer statistics, 2016
2016 Standout
Prospective evaluation of the clinical usefulness of an antigen- specific assay (MAIPA) in idiopathic thrombocytopenic purpura and other immune thrombocytopenias
1996
Is Cytosolic Ionized Calcium Regulating Neutrophil Activation?
1983 StandoutScienceNobel
Cancer statistics, 2015
2015 Standout
Peroxisome proliterators and cancer: mechanisms and implications
1986
Identification of genes differentially regulated by interferon α, β, or γ using oligonucleotide arrays
1998 Standout
The biology and treatment of acute lymphoblastic leukemia in adults
1995
A multidrug resistance transporter from human MCF-7 breast cancer cells
1998 Standout
Transient activation of c-MYC expression is critical for efficient platelet generation from human induced pluripotent stem cells
2010 StandoutNobel
Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase
2000 StandoutScience
In vitro granulocyte adherence and in vivo margination: two associated complement-dependent functions
1977
Cytokine therapeutics: lessons from interferonalpha.
1994
Large-scale analysis of the human and mouse transcriptomes
2002 StandoutNobel
GENETICS OF MYELOID LEUKEMIAS
2002
Nylon fiber leukapheresis: associated complement component changes and cranulocytopenia
1978
JNK1 controls mast cell degranulation and IL-1β production in inflammatory arthritis
2010 StandoutNobel
Treatments for chronic myeloid leukemia: a qualitative systematic review
2012
Interferon in Oncological Practice: Review of Interferon Biology, Clinical Applications, and Toxicities
2001
Complement activation and pulmonary leukotasis during nylon fiber filtration leukapheresis
1978
Chronic Myelogenous Leukemia: Biology and Therapy
1999
Works of CA Schiffer being referenced
Expression of multidrug resistance-associated protein (MRP) mRNA in blast cells from acute myeloid leukemia (AML) patients.
1996
The value of 10‐minute posttransfusion platelet counts
1988
The effects of postinduction intensification treatment with cytarabine and daunorubicin in adult acute lymphocytic leukemia: a prospective randomized clinical trial by Cancer and Leukemia Group B.
1991
An evaluation of combinations of diaziquone, etoposide and mitoxantrone in the treatment of adults with relapsed or refractory acute myeloid leukemia: results of 8722, a randomized phase II study conducted by Cancer and Leukemia Group B
1998
Expresssion of a 95 kDa membrane protein is associated with low daunorubicin accumulation in leukaemic blast cells
1995
Surgery in acute leukemia: A review of 167 operations in thrombocytopenic patients
1987
Hematopoietic growth factors as adjuncts to the treatment of acute myeloid leukemia
1996
Fate in Humans of the Plasticizer, Di‐2‐Ethylhexyl Phthalate, Arising from Transfusion of Platelets Stored in Vinyl Plastic Bags
1976
Prevention of alloimmunization against platelets [editorial]
1991
Minimally differentiated acute nonlymphocytic leukemia: a distinct entity
1987
Platelet transfusion therapy for alloimmunized patients: selective mismatching for HLA B12, an antigen with variable expression on platelets
1989
Alloimmunization following platelet transfusion: the absence of a dose- response relationship
1981
Selection of histocompatible apheresis platelet donors by cross- matching random donor platelet concentrates
1992
Alloimmunization following platelet transfusion: the absence of a dose- response relationship
1981
Synergistic reversal of multidrug-resistance phenotype in acute myeloid leukemia cells by cyclosporin A and cremophor EL
1994
Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: a Cancer and Leukemia Group B Study (8762)
1992
Prognostic importance of mutations in the ras proto-oncogenes in de novo acute myeloid leukemia
1994
Prognostic impact of cytogenetic abnormalities in patients with de novo acute nonlymphocytic leukemia
1989
Potential HLA‐matched platelet donor availability for alloimmunized patients
1983
Prolonged subcutaneous administration of recombinant alpha 2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: effect on remission duration and survival: Cancer and Leukemia Group B study 8583 [see comments]
1993
Enhancement of daunorubicin accumulation, retention, and cytotoxicity by verapamil or cyclosporin A in blast cells from patients with previously untreated acute myeloid leukemia
1993
Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: a Cancer and Leukemia Group B Study (8762)
1992
Detection of platelet antibodies using a micro-enzyme-linked immunosorbent assay (ELISA)
1983
Prevention of alloimmunization against platelets [editorial]
1991
Transient neutropenia induced by transfusion of blood exposed to nylon fiber filters
1975
Prognostic importance of mutations in the ras proto-oncogenes in de novo acute myeloid leukemia
1994
Serial measurement of lymphocytotoxic antibody and response to nonmatched platelet transfusions in alloimmunized patients
1987
Four-year follow-up of patients with chronic-phase chronic myeloid leukemia (CP-CML) receiving 100 mg of dasatinib once daily.
2010
High-dose intravenous gammaglobulin in alloimmunized platelet transfusion recipients
1984